rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PRAX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guggenheim raises Praxis Precision Medicines price target to $1,050
      Nov 16Investing.comPRAX
      Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)
      Nov 16Seeking AlphaPRAX
      H.C. Wainwright reiterates Buy on Praxis Precision stock at $1,201
      Nov 11Investing.comPRAX
      Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value

      Praxis Precision Medicines has delivered very strong multi year gains, and the latest move leaves investors asking whether the current share price still lines up with what its book value can support. With the story increasingly shaped by expectations rather than cash flow today, the question is how much balance sheet backing the stock really has at this level. Over the past 3 years, Praxis Precision Medicines has produced a return of roughly 24 times an initial investment. This puts a lot of...

      Nov 10Yahoo FinancePRAX
      Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
      Nov 9Investing.comPRAX
      Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
      Nov 9Yahoo FinancePRAX
      Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value
      Nov 9Yahoo FinancePRAX
      Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 4Yahoo FinancePRAX
      Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?
      Oct 28Yahoo FinancePRAX
      Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
      Oct 27Yahoo FinancePRAX
      Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Madrigal Pharmaceuticals (MDGL)

      Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

      Oct 19The Globe and MailPRAX
      Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?
      Oct 18Yahoo FinancePRAX
      JPMorgan Initiates Praxis Precision Medicines at Overweight With $700 Price Target
      Oct 16Yahoo FinancePRAX
      UBS Initiates Praxis Precision Medicines at Buy With $706 Price Target
      Oct 15Yahoo FinancePRAX
      Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Glaukos (GKOS) and Praxis Precision Medicines (PRAX)

      Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailIPSCPRAX
      Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)

      Tipranks Press Release.

      Oct 6The Globe and MailPRAXPRME
      Praxis Precision Medicine Q2 2026 Earnings Call Transcript - Praxis Precision Medicine (NASDAQ:PRAX)

      Praxis Precision Medicine (NASDAQ:PRAX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call

      Oct 6BenzingaPRAX
      Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the

      Oct 2Yahoo FinancePRAX
      Praxis Precision Medicine options signal ahead of two FDA decisions
      Sep 30Investing.comPRAX
      H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential
      Sep 24Investing.comPRAX
      Praxis Precision Medicines: Still Potential Upside After Huge Rally (NASDAQ:PRAX)
      Sep 12Seeking AlphaPRAX
      Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan

      Sep 3Yahoo FinancePRAX
      S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead
      Aug 31Barron'sPRAX
      Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

      Detailed price information for Tempus AI Cl A (TEM-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailPRAXUNCY

      This is the newest page. Registered accounts read further back.